Elevance Health

Q2 FY2026 EarningsQ2 2026 operating revenue reached $49.8B, up 0.8% YoY, supported by higher premium yields and CarelonRx growth despite membership declines. Adjusted diluted EPS was $7.45, exceeding expectations due to favorable benefit expense performance and a $0.80 per share below-the-line benefit. Benefit expense ratio rose 80bps to 89.7% on Government business trends. FY 2026 adjusted EPS guidance was raised to at least $27.00, with operating cash flow outlook increased to at least $6.0B.